Karin M Danzer

List of Publications by Year
in descending order

63 papers	6,187 citations	136950 32 h-index	123424 61 g-index
64 all docs	64 docs citations	64 times ranked	8631 citing authors

#	Article	IF	Citations
1	Different Species of Î±-Synuclein Oligomers Induce Calcium Influx and Seeding. Journal of Neuroscience, 2007, 27, 9220-9232.	3.6	708
2	Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular Neurodegeneration, 2012, 7, 42.	10.8	708
3	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
4	Induction of Î±-synuclein aggregate formation by CSF exosomes from patients with Parkinsonâ€™s disease and dementia with Lewy bodies. Brain, 2016, 139, 481-494.	7.6	349
5	Heatâ€shock protein 70 modulates toxic extracellular Î±â€synuclein oligomers and rescues transâ€synaptic toxicity. FASEB Journal, 2011, 25, 326-336.	0.5	276
6	TDP-43 is intercellularly transmitted across axon terminals. Journal of Cell Biology, 2015, 211, 897-911.	5.2	263
7	Seeding induced by Î±â€synuclein oligomers provides evidence for spreading of Î±â€synuclein pathology. Journal of Neurochemistry, 2009, 111, 192-203.	3.9	254
8	Inflammatory dysregulation of blood monocytes in Parkinsonâ€™s disease patients. Acta Neuropathologica, 2014, 128, 651-663.	7.7	216
9	Single Particle Characterization of Iron-induced Pore-forming Î±-Synuclein Oligomers. Journal of Biological Chemistry, 2008, 283, 10992-11003.	3.4	204
10	Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. PLoS Genetics, 2014, 10, e1004741.	3.5	168
11	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167
12	Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent Î±-Synuclein Oligomer Formation and Rescue Î±-Synuclein-Induced Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 849-857.	2.5	162
13	Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathologica, 2016, 131, 379-391.	7.7	140
14	Extracellular vesicle sorting of Î±-Synuclein is regulated by sumoylation. Acta Neuropathologica, 2015, 129, 695-713.	7.7	136
15	Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics, 2007, 7, 605-616.	2.2	122
16	Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathologica, 2016, 132, 391-411.	7.7	116
17	Mutual exacerbation of peroxisome proliferatorâ€activated receptor Î³ coactivator 1Î± deregulation and Î±â€synuclein oligomerization. Annals of Neurology, 2015, 77, 15-32.	5.3	112
18	NEK1mutations in familial amyotrophic lateral sclerosis. Brain, 2016, 139, e28-e28.	7.6	105

#	Article	IF	Citations
19	Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain, 2014, 137, e309-e309.	7.6	101
20	Increased Immune Activation by Pathologic Î±â€Synuclein in Parkinson's Disease. Annals of Neurology, 2019, 86, 593-606.	5.3	95
21	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain, 2014, 137, 2938-2950.	7.6	91
22	PGC-1Â is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 3477-3484.	2.9	74
23	Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 2660.e15-2660.e20.	3.1	64
24	AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced Î±-synuclein oligomers. Journal of Neurochemistry, 2011, 117, 868-878.	3.9	60
25	Release and uptake of pathologic alpha-synuclein. Cell and Tissue Research, 2018, 373, 175-182.	2.9	57
26	Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. Journal of Experimental Medicine, 2019, 216, 267-278.	8.5	57
27	Proteasome impairment by Î±-synuclein. PLoS ONE, 2017, 12, e0184040.	2.5	49
28	Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alphaâ€Synuclein as Revealed by Ion Mobility Mass Spectrometry. ChemBioChem, 2011, 12, 2740-2744.	2.6	44
29	Î±-Synuclein in Parkinson's Disease: Pathogenic Function and Translation into Animal Models. Neurodegenerative Diseases, 2014, 14, 1-17.	1.4	39
30	Impaired activation of ALS monocytes by exosomes. Immunology and Cell Biology, 2017, 95, 207-214.	2.3	39
31	Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not Î±-Synuclein-Induced Neuronal Cell Loss. PLoS ONE, 2014, 9, e86048.	2.5	35
32	ALS-causing mutations differentially affect PGC-1Î± expression and function in the brain vs. peripheral tissues. Neurobiology of Disease, 2017, 97, 36-45.	4.4	35
33	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cellular and Molecular Life Sciences, 2018, 75, 4301-4319.	5.4	34
34	Telomere shortening leads to earlier age of onset in ALS mice. Aging, 2016, 8, 382-393.	3.1	31
35	CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. Human Molecular Genetics, 2018, 27, 706-715.	2.9	30
36	Î±-synuclein interacts with SOD1 and promotes its oligomerization. Molecular Neurodegeneration, 2015, 10, 66.	10.8	29

#	Article	IF	Citations
37	LRRK2 contributes to monocyte dysregulation in Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2016, 4, 123.	5.2	29
38	The Role of Lipids in the Initiation of Î±-Synuclein Misfolding. Frontiers in Cell and Developmental Biology, 2020, 8, 562241.	3.7	29
39	InÂVivo Protein Complementation Demonstrates Presynaptic Î±-Synuclein Oligomerization and Age-Dependent Accumulation of 8â€“16-mer Oligomer Species. Cell Reports, 2019, 29, 2862-2874.e9.	6.4	26
40	SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden. Neurobiology of Aging, 2020, 87, 139.e9-139.e15.	3.1	23
41	T-cell dysregulation is associated with disease severity in Parkinsonâ€™s Disease. Journal of Neuroinflammation, 2021, 18, 250.	7.2	22
42	Quantifying amyloid fibrils in protein mixtures via infrared attenuated-total-reflection spectroscopy. Analytical and Bioanalytical Chemistry, 2015, 407, 4015-4021.	3.7	20
43	Screening forCHCHD10mutations in a large cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant: Table 1. Brain, 2016, 139, e8-e8.	7.6	20
44	Functional protein kinase arrays reveal inhibition of pâ€21â€activated kinase 4 by Î±â€synuclein oligomers. Journal of Neurochemistry, 2007, 103, 2401-2407.	3.9	18
45	The Golgi-Localized Î³-Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid-Î² Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1). PLoS ONE, 2015, 10, e0129047.	2.5	17
46	Aggregated Î±-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2016, 186, 2152-2161.	3.8	17
47	Hemizygous deletion of Tbk1 worsens neuromuscular junction pathology in TDP-43 transgenic mice. Experimental Neurology, 2021, 335, 113496.	4.1	15
48	Longitudinal diffusion tensor magnetic resonance imaging analysis at the cohort level reveals disturbed cortical and callosal microstructure with spared corticospinal tract in the TDP-43G298S ALS mouse model. Translational Neurodegeneration, 2019, 8, 27.	8.0	13
49	Intracellular Alpha-Synuclein and Immune Cell Function. Frontiers in Cell and Developmental Biology, 2020, 8, 562692.	3.7	13
50	Gelsolin co-occurs with Lewy bodies in vivo and accelerates Î±-synuclein aggregation in vitro. Biochemical and Biophysical Research Communications, 2011, 412, 32-38.	2.1	12
51	Protein Binding Partners of Dysregulated miRNAs in Parkinsonâ€™s Disease Serum. Cells, 2021, 10, 791.	4.1	11
52	Age Increases Monocyte Adhesion on Collagen. Scientific Reports, 2017, 7, 46532.	3.3	10
53	Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA. Journal of Virological Methods, 2020, 286, 113965.	2.1	10
54	Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. Brain Communications, 2020, 2, fcaa133.	3.3	9

#	Article	IF	Citations
55	Drug Targets from Genetics: Alpha-Synuclein. CNS and Neurological Disorders - Drug Targets, 2011, 10, 712-723.	1.4	9
56	Commentary: alpha-synuclein interacts with SOD1 and promotes its oligomerization. Journal of Neurology and Neuromedicine, 2016, 1, 28-30.	0.9	9
57	Enhanced Hyaluronan Signaling and Autophagy Dysfunction by VPS35 D620N. Neuroscience, 2020, 441, 33-45.	2.3	8
58	A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sclerosis. Brain, 2021, 144, 1214-1229.	7.6	8
59	Methylome analysis of ALS patients and presymptomatic mutation carriers in blood cells. Neurobiology of Aging, 2022, 116, 16-24.	3.1	8
60	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (Î±-syn) oligomerization and secretion. Aging, 2017, 9, 1677-1697.	3.1	7
61	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
62	Increased NF-L levels in the TDP-43G298S ALS mouse model resemble NF-L levels in ALS patients. Acta Neuropathologica, 2022, 144, 161-164.	7.7	1
63	Inside Cover: Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alpha-Synuclein as Revealed by Ion Mobility Mass Spectrometry (ChemBioChem 18/2011). ChemBioChem, 2011, 12, 2706-2706.	2.6	0